JOHNSON, Patrick Stephen,DACK, Kevin Neil,HENRIKSSON, Krister
申请号：
EP16775485
公开号：
EP3350175A1
申请日:
2016.09.13
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
wherein R1 is selected from the group consisting of 5- and 6-membered heteroaryl, (C1-C6)alkyl, (C3-C6)cycloalkyl, (4-6)-membered heterocycloalkyl and phenyl R2 is selected from (C1-C3)alkyl and halo(C1-C3)alkyl R3 is selected from phenyl, 5-membered heteroaryl and 6-membered heteroaryl R4 is selected from hydrogen, halogen, (C1-C4)alkyl and halo(C1-C4)alkyl X1 is selected from CH, C(Rb) and N, X2 is selected from CH and N Y is selected from —NH— and —O— m is 0 or 1 n is 0 or 1 L represents a bond, —O—, —NH— or —N(Rc)— or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.
